Cardiovascular specialists have been excited about the clinical results coming in for many of our difficult to treat hyperlipidemic patients with the new PCSK9 agents. We will delve into an important discussion on the “PCSK9 Revolution” at the annual Cardiovascular Disease Management: A Case-Based Approach, 6th Annual Symposium, which will take place October 11-12, 2018 at the Arizona Biltmore in Phoenix, AZ. Christie Ballantyne, an international lipid expert, will be joining us from the Baylor College of Medicine in Houston, Texas, to talk about these exciting agents and to present new data on anti-inflammatory agents in patients with cardiovascular disease.
I welcome your thoughts on the subject in the discussion below, and hope to see you in Phoenix this October!
Richard R. Heuser, MD, FACC
Chief of Cardiology
St. Luke’s Medical Center
Professor of Medicine
University of Arizona College of Medicine